相关实验视频

Updated: Jul 20, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

精制肝细胞模型以捕捉CYP2D6*10的影响,使用PITCh系统

Ryosuke Negoro¹, Ayu Ouchi¹, Sayaka Deguchi²

¹Laboratory of Molecular Pharmacokinetics, College of Pharmaceutical Sciences, Ritsumeikan University.

Biological & pharmaceutical bulletin

|August 7, 2024

概括

在东亚人中常见的CYP2D6*10变种降低了药物代谢. 研究人员创建了一个新的HepG2细胞模型,表达这种变体,以更好地预测这种人群中的药物效应.

科学领域:

药物基因组学药物基因组学
药物新陈代谢药物新陈代谢
遗传学遗传学是一个

背景情况:

CYP2D6*10是一种在东亚人群中普遍存在的,不太活跃的变体,导致药物代谢减少.
这种变异导致了胺替代的普罗林,降低了CYP2D6的稳定性和代谢功能.
在东亚人中准确预测药物代谢和毒性需要考虑CYP2D6*10.的模型.

研究的目的:

开发和验证一种稳定表达CYP2D6*10变异的HepG2细胞系.
通过基因组编辑来研究CYP2D6*10对肝脏药物代谢的影响.
为研究东亚人药物代谢和肝毒性建立可靠的模型.

主要方法:

利用精确集成到目标染色体 (PITCh) 系统进行基因组编辑.
生成的HepG2细胞 (CYP2D6*10 KI-HepG2),表达CYP2D6*10和其他关键药物代谢酶.
在工程和对照细胞系之间比较CYP2D6蛋白表达和代谢活性.

主要成果:

成功生成CYP2D6*10KI-HepG2细胞,具有功能CYP2D6*10和其他酶的稳定表达.
与对照组相比,在CYP2D6*10 KI-HepG2细胞中观察到降低的CYP2D6蛋白水平和代谢活性.
验证了工程细胞作为研究CYP2D6*10介导药物代谢的模型.

结论:

CYP2D6*10 KI-HepG2细胞为肝脏代谢研究提供了宝贵的工具.
这种模型对于预测东亚人口的药物反应和潜在毒性至关重要.
这项研究强调了基因变异在药物代谢和个性化医学中的重要性.

关键词:

在CYP2D6中.由于CYP2D6*10的存在,在HepG2细胞中,HepG2细胞聚类有规律间隔的短平行体重复-CRISPR相关的9 (CRISPR-Cas9) 系统.基因组编辑基因组编辑主要的人类肝细胞.

更多相关视频

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...